The fragility index : how robust are the outcomes of head and neck cancer randomised, controlled trials?
BACKGROUND: The fragility index represents the minimum number of patients required to convert an outcome from statistically significant to insignificant. This report assesses the fragility index of head and neck cancer randomised, controlled trials.
METHODS: Studies were extracted from PubMed/Medline, Scopus, Embase and Cochrane databases.
RESULTS: Overall, 123 randomised, controlled trials were included. The sample size and fragility index medians (interquartile ranges) were 103 (56-213) and 2 (0-5), respectively. The fragility index exceeded the number of patients lost to follow up in 42.3 per cent (n = 52) of studies. A higher fragility index correlated with higher sample size (r = 0.514, p < 0.001), number of events (r = 0.449, p < 0.001) and statistical significance via p-value (r = -0.367, p < 0.001).
CONCLUSION: Head and neck cancer randomised, controlled trials demonstrated low fragility index values, in which statistically significant results could be nullified by altering the outcomes of just two patients, on average. Future head and neck oncology randomised, controlled trials should report the fragility index in order to provide insight into statistical robustness.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:138 |
|---|---|
| Enthalten in: |
The Journal of laryngology and otology - 138(2024), 4 vom: 23. März, Seite 451-456 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Suresh, Neeraj V [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer of the head |
|---|
| Anmerkungen: |
Date Completed 20.03.2024 Date Revised 21.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1017/S0022215123001755 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362894299 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362894299 | ||
| 003 | DE-627 | ||
| 005 | 20240321235508.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1017/S0022215123001755 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1338.xml |
| 035 | |a (DE-627)NLM362894299 | ||
| 035 | |a (NLM)37795709 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Suresh, Neeraj V |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The fragility index |b how robust are the outcomes of head and neck cancer randomised, controlled trials? |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.03.2024 | ||
| 500 | |a Date Revised 21.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: The fragility index represents the minimum number of patients required to convert an outcome from statistically significant to insignificant. This report assesses the fragility index of head and neck cancer randomised, controlled trials | ||
| 520 | |a METHODS: Studies were extracted from PubMed/Medline, Scopus, Embase and Cochrane databases | ||
| 520 | |a RESULTS: Overall, 123 randomised, controlled trials were included. The sample size and fragility index medians (interquartile ranges) were 103 (56-213) and 2 (0-5), respectively. The fragility index exceeded the number of patients lost to follow up in 42.3 per cent (n = 52) of studies. A higher fragility index correlated with higher sample size (r = 0.514, p < 0.001), number of events (r = 0.449, p < 0.001) and statistical significance via p-value (r = -0.367, p < 0.001) | ||
| 520 | |a CONCLUSION: Head and neck cancer randomised, controlled trials demonstrated low fragility index values, in which statistically significant results could be nullified by altering the outcomes of just two patients, on average. Future head and neck oncology randomised, controlled trials should report the fragility index in order to provide insight into statistical robustness | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Clinical trials, randomized | |
| 650 | 4 | |a cancer of the head | |
| 650 | 4 | |a cancer of the neck | |
| 650 | 4 | |a otolaryngology | |
| 650 | 4 | |a statistics | |
| 700 | 1 | |a Go, Beatrice C |e verfasserin |4 aut | |
| 700 | 1 | |a Fritz, Christian G |e verfasserin |4 aut | |
| 700 | 1 | |a Harris, Jacob |e verfasserin |4 aut | |
| 700 | 1 | |a Ahluwalia, Vinayak |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Katherine |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Joseph |e verfasserin |4 aut | |
| 700 | 1 | |a Rajasekaran, Karthik |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of laryngology and otology |d 1945 |g 138(2024), 4 vom: 23. März, Seite 451-456 |w (DE-627)NLM000061794 |x 1748-5460 |7 nnns |
| 773 | 1 | 8 | |g volume:138 |g year:2024 |g number:4 |g day:23 |g month:03 |g pages:451-456 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1017/S0022215123001755 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 138 |j 2024 |e 4 |b 23 |c 03 |h 451-456 | ||